Cantor Fitzgerald Weighs in on Valeant Pharmaceuticals Intl Inc’s FY2018 Earnings (VRX)

Valeant Pharmaceuticals Intl Inc (TSE:VRX) (NYSE:VRX) – Investment analysts at Cantor Fitzgerald upped their FY2018 earnings per share (EPS) estimates for Valeant Pharmaceuticals Intl in a report issued on Sunday, according to Zacks Investment Research. Cantor Fitzgerald analyst L. Chen now anticipates that the specialty pharmaceutical company will earn $3.83 per share for the year, up from their prior forecast of $3.77.

Valeant Pharmaceuticals Intl (TSE VRX) traded up C$1.12 on Wednesday, hitting C$21.98. 1,850,282 shares of the company were exchanged, compared to its average volume of 1,809,298. Valeant Pharmaceuticals Intl has a one year low of C$11.20 and a one year high of C$30.56. The company has a market capitalization of $7,260.00, a price-to-earnings ratio of 4.20 and a beta of -0.76.

TRADEMARK VIOLATION WARNING: This report was published by The Lincolnian Online and is owned by of The Lincolnian Online. If you are reading this report on another site, it was illegally stolen and republished in violation of US & international copyright & trademark law. The correct version of this report can be viewed at

About Valeant Pharmaceuticals Intl

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

Get a free copy of the Zacks research report on Valeant Pharmaceuticals Intl (VRX)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Valeant Pharmaceuticals Intl Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals Intl and related companies with's FREE daily email newsletter.

Leave a Reply